|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
|
Further information
|
Invitation to participate
|
| Process |
STA Standard
|
| ID number |
6411
|
Provisional Schedule
| Expected publication |
12 February 2025 |
Project Team
Email enquiries
| External Assessment Group |
Centre for Reviews and Dissemination and Centre for Health Economics, University of York |
Stakeholders
| Companies sponsors |
AstraZeneca (dapagliflozin) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Kidney Research UK |
| Professional groups |
Royal College of Physicians |
| |
UK Kidney Association |
| Comparator companies |
Boehringer Ingelheim (empagliflozin) |
| General commentators |
All Wales Therapeutic and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health - Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare Products Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
National Institute for Health & Care Research |
|
Date
|
Update
|
|
17 May 2024
|
Invitation to participate |
|
17 May 2024
|
Invitation to participate |
|
17 May 2024
|
In progress |
For further information on how we select topics for development, please see our page about topic selection